Pemazyre Pemazyre

Pemazyre（pemigatinib）

Company: Incyte Corporation

Approval Status: Approved on 4/17/2020

Specific treatment: Cholangiocarcinoma

Mechanism of Action:

Pemigatinib is a small molecule kinase inhibitor that targets FGFR1, 2 and 3 with IC50 values of less than 2 nM. Pemigatinib also inhibited FGFR4 in vitro at a concentration approximately 100 times higher than those that inhibit FGFR1, 2, and 3. Pemigatinib inhibited FGFR1-3 phosphorylation and signaling and decreased cell viability in cancer cell lines with activating FGFR amplifications and fusions that resulted in constitutive activation of FGFR signaling. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Pemigatinib exhibited anti-tumor activity in mouse xenograft models of human tumors with FGFR1, FGFR2, or FGFR3 alterations resulting in constitutive FGFR activation including a
 patient-derived xenograft model of cholangiocarcinoma that expressed an oncogenic FGFR2­
 Transformer-2 beta homolog (TRA2b) fusion protein. 

Dosage form/Route:

Tablets: 4.5 mg, 9 mg, and 13.5 mg

Side effects:

The most common adverse reactions (incidence ≥ 20%) are hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin.